Randomized evidence for vaccine immunogenicity and safety is urgently needed in the setting of pandemics with new emerging infectious agents. We carried out an observational survey to evaluate how many randomized controlled trials testing 2009 H1N1 vaccines were published among those registered, and what was the time lag from their start to publication and from their completion to publication.PubMed, EMBASE and 9 clinical trial registries were searched for eligible randomized controlled trials. The units of the analysis were single randomized trials on any individual receiving influenza vaccines in any setting.73 eligible trials were identified that had been registered in 2009–2010. By June 30, 2011 only 21 (29%) of these trials had been pu...
BACKGROUND:New emerging infections have no known treatment. Assessing potential drugs for safety and...
The emergence of pandemic H1N1 influenza in 2009 has prompted public health responses, including pro...
We find ourselves at a momentous turn in the history of vaccines. The COVID-19 pandemic triggered a ...
Randomized evidence for vaccine immunogenicity and safety is urgently needed in the setting of pande...
Background: Randomized evidence for vaccine immunogenicity and safety is urgently needed in the sett...
BACKGROUND: Randomized evidence for vaccine immunogenicity and safety is urgently needed in the sett...
Objective To evaluate the extent of non-publication or delayed publication of registered randomized...
Objective To evaluate the extent of non-publication or delayed publication of registered randomized...
Abstract Background Pandemic events often trigger a surge of clinical trial activity aimed at rapidl...
Background In contrast to the gradual pace of conventional vaccine trials, evaluation of influenza v...
<p>Time from start to publication for 2009 H1N1 vaccine trials overall (A) and according to sponsor ...
Objectives: Controlled human infection, the intentional infection of healthy volunteers, allows dise...
BACKGROUND: Neuraminidase inhibitors were used to reduce the transmission of pandemic influenza A/H1...
In April 2009, a novel influenza A virus emerged in the United States. By the end of July, influenza...
Introduction: Despite longstanding recommendations by public-health authorities vaccination coverage...
BACKGROUND:New emerging infections have no known treatment. Assessing potential drugs for safety and...
The emergence of pandemic H1N1 influenza in 2009 has prompted public health responses, including pro...
We find ourselves at a momentous turn in the history of vaccines. The COVID-19 pandemic triggered a ...
Randomized evidence for vaccine immunogenicity and safety is urgently needed in the setting of pande...
Background: Randomized evidence for vaccine immunogenicity and safety is urgently needed in the sett...
BACKGROUND: Randomized evidence for vaccine immunogenicity and safety is urgently needed in the sett...
Objective To evaluate the extent of non-publication or delayed publication of registered randomized...
Objective To evaluate the extent of non-publication or delayed publication of registered randomized...
Abstract Background Pandemic events often trigger a surge of clinical trial activity aimed at rapidl...
Background In contrast to the gradual pace of conventional vaccine trials, evaluation of influenza v...
<p>Time from start to publication for 2009 H1N1 vaccine trials overall (A) and according to sponsor ...
Objectives: Controlled human infection, the intentional infection of healthy volunteers, allows dise...
BACKGROUND: Neuraminidase inhibitors were used to reduce the transmission of pandemic influenza A/H1...
In April 2009, a novel influenza A virus emerged in the United States. By the end of July, influenza...
Introduction: Despite longstanding recommendations by public-health authorities vaccination coverage...
BACKGROUND:New emerging infections have no known treatment. Assessing potential drugs for safety and...
The emergence of pandemic H1N1 influenza in 2009 has prompted public health responses, including pro...
We find ourselves at a momentous turn in the history of vaccines. The COVID-19 pandemic triggered a ...